ArticleDiscover oncology2025
A deep learning model for multiclass lung cancer classification using multimodal data fusion.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionLung cancer is the most prevalent malignant tumour in terms of morbidity and mortality. Accurate classification and risk staging are essential for developing appropriate treatment plans and achieving precision in lung cancer diagnosis and treatment.
methodA lung cancer pathological image classification model was trained using ResNet152. The image input structure of ResNet152 was modified to support custom input image block sizes. A multimodal deep learning model (MMLM) was developed that integrated features extracted from the trained ResNet152 (RNet), standardized RNA sequencing data, methylation microarray data, and clinical information through a feature-level fusion method. This process emulates the way in which pathologists integrate multimodal information to make decisions. The incorporation of Class Activation Mapping (CAM) and UMAP mapping enhanced the interpretability of the model, thus increasing its transparency and fostering greater trust in its decision-making process.
resultsIn the context of lung cancer classification on an independent test set, compared with monomodality RNet, the MMLM demonstrated superior performance. The areas under the curve (AUC) values of the MMLM were 0.999, 1.000, and 0.980, which significantly surpassed RNet’s values of 0.822, 0.732, and 0.781, respectively. Similarly, the average precision (AP) values of the MMLM were 0.999, 1.000, and 0.909, which surpassed those of RNet (0.793, 0.606, and 0.471). In addition, supplementary validation of the ability of the MMLM to predict lung cancer risk staging yielded encouraging results.
conclusionsThe MMLM integrates pathological images, RNA sequencing data, methylation data, and clinical information to improve lung cancer classification and prognosis. However, challenges remain, such as limited access to comprehensive clinical data, patient privacy concerns, and computational resource demands. The MMLM holds significant potential to become a powerful tool for personalized lung cancer diagnosis and treatment with continued advancements in data integration and privacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.